Equibles does not estimate personal net worth.
Get an email with a short summary when Mirum Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get MIRM alertsPeter Radovich is recorded as COO at Mirum Pharmaceuticals, Inc. (MIRM). The newest filing on record that lists Peter Radovich as COO at Mirum Pharmaceuticals, Inc. (MIRM) is dated April 23, 2024. Mirum Pharmaceuticals, Inc. reported in an 8-K filed January 16, 2024 that Peter Radovich was appointed President, effective January 16, 2024. The proxy statement of Mirum Pharmaceuticals, Inc. reports total compensation of $3,964,270 for Peter Radovich in fiscal 2025, including a base salary of $572,500. Disclosed compensation is on record for 6 fiscal years. Peter Radovich has spoken on 20 earnings calls and 2 other investor events across 1 company, most recently for Mirum Pharmaceuticals, Inc. on November 3, 2026. Mirum Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Mirum Pharmaceuticals, Inc. includes Christopher Peetz (CEO), Michael Grey (CEO), Eric Bjerkholt (CFO) and 5 others.
“On January 11, 2024, the Board of Directors of Mirum Pharmaceuticals, Inc. (the "Company") promoted Peter Radovich, previously the Company's Chief Operating Officer, to the additional position of President, with Christopher Peetz, who previously served as the Company's President and Chief Executive Officer, continuing to serve as the Company's Chief Executive Officer, each effective as of January 16, 2024.”
“The third quarter was another excellent quarter for Barium's commercial business, with $186 million in net product sales. But Marley continues to be the primary growth driver, with third quarter net product sales of $133 million, including $100 million in the United States.”
“The second quarter was another strong quarter for Merrim's commercial business, with total net product sales of 176 million. The Marley and the BioAcid Medicines both continue to perform well, and based on the demand we see, we are increasing our full year 2026 net product sales guidance to $680 to $700 million.”
“First, just wanted to remind the audience we'll be making forward-looking statements here today. And, of course, I would refer you to our SEC filings for full disclosures and risk factors.”
“I appreciate you and the organizers, including us. And before jumping into it, I just want to say we will be making forward-looking statements. So, of course, refer you to the risk factors and our disclosures on file with the SEC.”
“The first quarter was another period of strong commercial execution with total net product sales of approximately $160 million. This included Livemarly net product sales of $84 million in the U.S. and $30 million internationally, with the bio-asset medicines contributing $46 million.”
2024-01-16–present
Start not stated–present
Last confirmed April 23, 2024
Biotechnology · Healthcare
COO
2024-01-16–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Mirum Pharmaceuticals, Inc. (MIRM) | President and Chief Operating Officer | $572,500 | $3,964,270 |
| 2024 | Mirum Pharmaceuticals, Inc. (MIRM) | President and Chief Operating Officer | $550,000 | $3,337,856 |
| 2023 | Mirum Pharmaceuticals, Inc. (MIRM) | President and Chief Operating Officer | $505,000 | $2,367,484 |
| 2022 | Mirum Pharmaceuticals, Inc. (MIRM) | President and Chief Operating Officer | $467,500 | $1,561,446 |
| 2021 | Mirum Pharmaceuticals, Inc. (MIRM) | Chief Operating Officer | $425,000 | $1,803,029 |
| 2020 | Mirum Pharmaceuticals, Inc. (MIRM) | Chief Operating Officer | $277,992 | $2,644,820 |
